Why Target the Gut to Treat IgA Nephropathy?
Kidney Int Rep
.
2020 Aug 20;5(10):1620-1624.
doi: 10.1016/j.ekir.2020.08.009.
eCollection 2020 Oct.
Authors
Jonathan Barratt
1
,
Brad H Rovin
2
,
Daniel Cattran
3
,
Jürgen Floege
4
,
Richard Lafayette
5
,
Vladimir Tesar
6
,
Hernán Trimarchi
7
,
Hong Zhang
8
;
NefIgArd Study Steering Committee
Affiliations
1
Department of Cardiovascular Sciences, University of Leicester and Leicester General Hospital, Leicester, UK.
2
Division of Nephrology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
3
Toronto General Hospital Research Institute, Toronto, Ontario, Canada.
4
University Hospital, Rheinisch Westfälische Technische Hochschule, Aachen, Germany.
5
Stanford Glomerular Disease Center, Stanford University Medical Center, Stanford, California, USA.
6
General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic.
7
Department of Nephrology, Nephrology Service and Kidney Transplant Unit, Hospital Británico de Buenos Aires, Buenos Aires, Argentina.
8
Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
PMID:
33102954
PMCID:
PMC7569689
DOI:
10.1016/j.ekir.2020.08.009
No abstract available
Publication types
Editorial